Giant cell interstitial pneumonia in a 15-year-old boy

Tomoyuki Kakugawa1, Hiroshi Mukae, Towako Nagata

  • 1Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.

Insights

Giant cell interstitial pneumonia (GIP) is a rare lung disease. This report details the youngest known GIP patient, a 15-year-old, highlighting unique diagnostic and treatment findings.

Area of Science:

  • Pulmonology
  • Pathology
  • Toxicology

Background:

  • Giant cell interstitial pneumonia (GIP) is an exceptionally rare interstitial lung disease.
  • Etiology often involves occupational or environmental exposures, particularly to hard metals like cobalt and tungsten.
  • Previous reports indicate a higher incidence in adults, with limited data on pediatric cases.

Observation:

  • A 15-year-old male presented with symptoms consistent with GIP.
  • Lung biopsy revealed characteristic interstitial infiltrates, intraalveolar macrophages, and multinucleated giant cells with emperipolesis.
  • Despite negative tissue analysis for cobalt and tungsten, potential parental exposure was considered.

Findings:

  • The patient, the world's youngest reported GIP case, showed significant improvement with corticosteroid therapy.
  • This case adds to the limited understanding of GIP in Japan, with only eleven previously reported instances.
  • No clear dose-response relationship between hard metal exposure and GIP onset or prognosis has been established in prior Japanese cases.

Implications:

  • This case underscores the importance of considering GIP in young patients presenting with interstitial lung disease, even without a clear exposure history.
  • The favorable response to corticosteroids suggests a potential therapeutic avenue for GIP, irrespective of identified causative agents.
  • Further research is needed to elucidate the pathogenesis and identify potential environmental triggers for GIP, particularly in younger populations.

Related Concept Videos

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...